Monoclonal antibody strategies to block angiogenesis

Drug Discovery Today

Volumn 6, Issue 10, 2001, Pages 517-528

  Hicklin, Daniel J ^a   Witte, Larry ^a   Zhu, Zhenping ^a   Liao, Fang ^a   Wu, Yan ^a   Li, Yiwen ^a   Bohlen, Peter ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ANGIOGENESIS; CANCER; CANCER RESEARCH; DRUG DEVELOPMENT; ENDOTHELIUM CELL; HUMAN; NONHUMAN; REVIEW; TUMOR GROWTH;

EID: 0035336732     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01759-7     Document Type: Review

References (80)

1. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
2. Miller R.A., et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New Engl. J. Med. 306:1982;517-522.
3. Glennie M.J., Johnson P.W.M. Clinical trials of antibody therapy. Immunol. Today. 21:2000;403-410.
4. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77:1999;527-543.
5. Hiratsuka S., et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;9349-9354.
6. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin. Canc. Biol. 3:1999;211-220.
7. Witte L., et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17:1998;155-161.
8. Zhu Z., Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest. New. Drugs. 17:1999;195-212.
9. Kim K.J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
10. Warren R.S., et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95:1995;1789-1797.
11. Borgstrom P., et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate. 35:1998;1-10.
12. Mesiano S., et al. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Amer. J. Pathol. 153:1998;1249-1256.
13. Yuan F., et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. U. S. A. 93:1996;14765-14770.
14. Borgstrom P., et al. Complete inhibition of angiogenesis and growth of microtumours by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56:1996;4032-4039.
15. Presta L.G., et al. Humanization of an anti-vascular endothelial growth factor mAb for the therapy of solid tumors and other disorders. Cancer Res. 57:1997;4593-4599.
16. Ryan A.M., et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized mAb. Toxicol. Pathol. 27:1999;78-86.
17. Asano M., et al. An anti-human VEGF mAb, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma. 17:1998;185-190.
18. Brekken R.A., et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60:2000;5117-5124.
19. Achen M.G., et al. MAb to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Eur. J. Biochem. 267:2000;2505-2515.
20. Rockwell P., et al. In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody. Mol. Cell. Diff. 3:1995;91-109.
21. Skobe M., et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3:1997;1222-1227.
22. Prewett M., et al. Anti-VEGF receptor (Flk-1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:1999;5209-5218.
23. Yoshiji H., et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology. 30:1999;1179-1186.
24. Bruns C.J., et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal liver metastases. Cancer. 89:2000;488-499.
25. Inoue K., et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Canc. Res. 6:2000;2635-2643.
26. Kozin, S.V. et al. Vascular Endothelial Growth Factor Receptor-2 blockade selectively increases radiation-induced cure rate of human tumor xenografts. Cancer Res. (in press).
27. Kerbel R.S., et al. Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Canc. 36:2000;1248-1257.
28. Klement G., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;R15-R24.
29. Zhu Z., et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. 58:1998;3209-3214.
30. Zhu Z., et al. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett. 136:1999;203-213.
31. Lu D., et al. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J. Biol. Chem. 275:2000;14321-14330.
32. Dias S., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106:2000;511-521.
33. Pavco P.A., et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Canc. Res. 5:2000;2094-2103.
34. Kanno S., et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene. 19:2000;2138-2146.
35. Kaipainen A., et al. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to endothelium of lymphatic vessels during development. Proc. Natl. Acad. Sci. U. S. A. 92:1995;3566-3570.
36. Wilting J., et al. The avian VEGF receptor homologues Queck1 and Queck2 during quail embryonic development: expression in blood-vascular and lymphatic endothelial and non-endothelial cells. Cell Tissue Res. 288:1997;207-223.
37. Kubo H., et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood. 96:2000;546-553.
38. Hu D., et al. Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. Inflammation. 18:1994;45-58.
39. Reilly T., et al. MAb directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo. Biochem. Biophys. Res. Commun. 164:1989;736-743.
40. Coppola G., et al. Effect of intraperitoneally, intravenously and intralesionally administered monoclonal anti-beta-FGF antibodies on rat chondrosarcoma tumor vascularization and growth. Anticancer Res. 17:1997;2033-2039.
41. Satoh H., et al. Role of endogenous basic fibroblast growth factor in the healing of gastric ulcers in rats. Jpn. J. Pharmacol. 73:1997;59-71.
42. Hori A., et al. Suppression of solid tumor growth by immunoneutralizing mAb against human basic fibroblast growth factor. Cancer Res. 51:1991;6180-6184.
43. Nemati M., et al. Inhibition of angiogenesis and growth of malignant gliomas in the athymic nude rat model: immunotherapy against basic fibroblast growth factor. Zentralbl. Neurochir. 57:1996;12-19.
44. Lees V., Fan T.P. A freeze-injured skin graft model for the quantitative study of basic fibroblast growth factor and other promoters of angiogenesis in wound healing. Br. J. Plast. Surg. 47:1994;349-359.
45. Waksal H.W. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. 18:1999;427-436.
46. Petit A.M., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Amer. J. Pathol. 151:1997;1523-1530.
47. Bruns C.J., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Canc. Res. 6:2000;1936-1948.
48. Perrotte P., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Canc. Res. 5:2000;257-265.
49. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Canc. Res. 6:2000;2166-2174.
50. Ciardiello F., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Canc. Res. 6:2000;3739-3747.
51. 3 for angiogenesis. Science. 264:1994;569-571.
52. Stromblad S., Cheresh D. Cell adhesion and angiogenesis. Trends Cell. Biol. 6:1996;462-468.
53. 3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 18:1999;882-892.
54. v integrins. Science. 270:1995;500-502.
55. Kubota Y., et al. CDw49b/CD29 integrin complex mediates the differentiation of human endothelial cells into capillary-like structures in vitro. J. Dermatol. Sci. 12:1996;36-43.
56. Bader B., et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell. 95:1998;507-519.
57. 3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell. Sci. 108:1995;2655-2661.
58. 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1995;1815-1822.
59. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
60. Gumbiner B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 84:1996;345-357.
61. Dejana E., et al. Vascular endothelial (VE)-cadherin: only an intercellular glue. Exp. Cell. Res. 252:1999;13-19.
62. Carmeliet P., et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 98:1999;147-157.
63. Liao F., et al. Monoclonal antibody to vascular endothelial (VE)-cadherin is a potent inhibitor of angiogenesis, tumor growth and metastasis. Cancer Res. 60:2000;6805-6810.
64. Corada M., et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9815-9820.
65. Fett J., et al. A mAb to human angiogenin. Inhibition of ribonucleolytic and angiogenic activities and localization of the antigenic epitope. Biochemistry. 33:1994;5421-5427.
66. Olson K., et al. A mAb to human angiogenin suppresses tumor growth in athymic mice. Cancer Res. 54:1994;4576-4579.
67. Olson K., et al. Angiogenin antagonists prevent tumor growth in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:1995;442-446.
68. Piccoli R., et al. Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4579-4583.
69. Chesney J., et al. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5:1999;181-191.
70. Burrows F.J., Thorpe P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8996-9000.
71. Huang X., et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
72. Miller D.W., et al. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Intl. J. Cancer. 81:1999;568-572.
73. Maier J.A., et al. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM1470 (TNP470) and the anti-endoglin antibody TEC11. Anticancer Drugs. 8:1997;238-244.
74. Seon B.K., et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Canc. Res. 3:1997;1031-1044.
75. Matsuno F., et al. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin mAb. Clin. Canc. Res. 5:1999;371-382.
76. Thorpe P., Burrows F. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res. Treat. 36:1995;237-251.
77. Ohizumi I., et al. Suppression of solid tumor growth by a mAb against tumor vasculature in rats: involvement of intravascular thrombosis and fibrinogenesis. Intl. J. Cancer. 82:1999;853-859.
78. Carnemolla B., et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Intl. J. Cancer. 68:1996;397-405.
79. Viti F., et al. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59:1999;347-352.
80. Berndorff D., et al. A high-affinity human antibody that targets tumoral blood vessels. Blood. 94:1999;192-198.